Disease Domain | Count |
---|---|
Nervous System Diseases | 5 |
Endocrinology and Metabolic Disease | 5 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Target- |
Mechanism- |
Active Org. Jupiter Neurosciences, Inc.Startup |
Originator Org. Jupiter Neurosciences, Inc.Startup |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. Jupiter Neurosciences, Inc.Startup |
Originator Org. Jupiter Neurosciences, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. Jupiter Neurosciences, Inc.Startup |
Originator Org. Jupiter Neurosciences, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date21 Jan 2021 |
Sponsor / Collaborator Jupiter Neurosciences, Inc.Startup [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
JNS-101 | Friedreich Ataxia More | Phase 2 |
JNS108 | - | Phase 2 |
JNS-110 | Brain Concussion More | Phase 1 Clinical |
JNS107 | MELAS Syndrome More | Phase 1 |
JNS102 | Mucopolysaccharidosis I More | Phase 1 |